Using special hydrogels with camptothecin to improve treatment for brain tumors.
Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant Glioma
This study is testing a new way to deliver the cancer drug camptothecin directly to the brain after surgery for glioblastoma, with the hope of improving treatment and helping patients live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10919803 on NIH RePORTER |
What this research studies
This research focuses on developing innovative self-assembling nanofiber hydrogels that incorporate the anticancer drug camptothecin for treating malignant gliomas, particularly glioblastoma. After surgical removal of the tumor, these hydrogels will be applied to the resection site to provide localized and sustained release of the drug, potentially enhancing its effectiveness. The goal is to improve patient outcomes by extending survival times through better delivery of chemotherapy directly to the affected brain tissue.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with malignant gliomas, including glioblastoma, who are undergoing surgical treatment.
Not a fit: Patients with non-malignant brain tumors or those who are not candidates for surgical intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to significantly improved survival rates for patients with malignant gliomas.
How similar studies have performed: Previous research has shown that localized chemotherapy can extend survival in brain tumor patients, suggesting that this novel approach may also be effective.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Cui, Honggang — Johns Hopkins University
- Study coordinator: Cui, Honggang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.